Incyte vs Trimble Ag Software

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (93 vs 95)
Incyte logo

Incyte

LeaderHealthcare Tech

Enterprise

Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.

AI VisibilityBeta
Overall Score
A93
Category Rank
#20 of 290
AI Consensus
65%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
85
Gemini
95

About

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.

Full profile
Trimble Ag Software logo

Trimble Ag Software

LeaderAgriculture

Precision Agriculture

Trimble (NASDAQ: TRMB) precision agriculture software with GPS guidance and variable rate application for farm management; competing with John Deere Operations Center and Climate FieldView for crop data platform.

AI VisibilityBeta
Overall Score
A95
Category Rank
#2 of 4
AI Consensus
92%
Trend
stable
Per Platform
ChatGPT
95
Perplexity
93
Gemini
94

About

Trimble Ag Software is the precision agriculture software division of Trimble Inc. (NASDAQ: TRMB) — a Sunnyvale, California-based positioning and workflow technology company with $3.7 billion in annual revenue — providing farmers, agronomists, and farm managers with field mapping, GPS-guided variable rate application, crop record management, and agronomic analytics that enable data-driven farming decisions across planting, spraying, harvesting, and soil management. Operating under the Trimble Agriculture brand with products including Trimble TMX-2050, Trimble Farmer Core/Pro/Premium, and the Trimble Connected Farm suite, the division serves large-scale crop producers and ag service providers in North America, Europe, and Australia.

Full profile

AI Visibility Head-to-Head

93
Overall Score
95
#20
Category Rank
#2
65
AI Consensus
92
stable
Trend
stable
99
ChatGPT
95
85
Perplexity
93
95
Gemini
94
99
Claude
96
97
Grok
96

Capabilities & Ecosystem

Capabilities

Only Trimble Ag Software
Precision Agriculture

Integrations

Only Incyte

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.